Profile data is unavailable for this security.
About the company
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
- Revenue in USD (TTM)2.96bn
- Net income in USD122.68m
- Incorporated2019
- Employees6.13k
- LocationBiontech SEAn der Goldgrube 12MAINZ 55131GermanyDEU
- Phone+49 49 613190840
- Fax+49 61 319084390
- Websitehttps://www.biontech.com/
Mergers & acquisitions
Acquired company | 22UA:GER since announced | Transaction value |
---|---|---|
AexeRNA Therapeutics LLC | -7.04% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Legend Biotech Corp (ADR) | 342.80m | -465.95m | 10.32bn | 1.80k | -- | 8.86 | -- | 30.10 | -2.60 | -2.60 | 1.90 | 6.39 | 0.2297 | 9.52 | 203.86 | 190,443.30 | -31.22 | -37.71 | -37.33 | -47.19 | 52.35 | -- | -135.92 | -286.51 | 5.57 | -24.44 | 0.2233 | -- | 143.70 | 42.15 | -16.11 | -- | 1.57 | -- |
Medpace Holdings Inc | 2.03bn | 339.64m | 11.83bn | 5.80k | 35.87 | 15.45 | 32.15 | 5.83 | 10.63 | 10.63 | 63.59 | 24.69 | 1.22 | -- | 7.05 | 344,075.90 | 20.43 | 13.94 | 45.87 | 23.18 | 28.52 | 28.84 | 16.74 | 15.23 | -- | -- | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
Charles River Lbrtrs ntrntl Inc | 4.11bn | 438.82m | 12.03bn | 20.00k | 27.40 | 3.30 | 15.55 | 2.93 | 8.52 | 8.52 | 79.74 | 70.67 | 0.5187 | 8.38 | 5.22 | 205,579.80 | 5.69 | 6.46 | 6.53 | 7.62 | 36.45 | 36.99 | 10.97 | 11.58 | 1.37 | 4.80 | 0.4183 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
Insmed Inc | 315.49m | -746.89m | 12.16bn | 912.00 | -- | -- | -- | 38.53 | -5.23 | -5.23 | 2.20 | -3.13 | 0.2357 | 0.8971 | 9.32 | 345,936.40 | -55.80 | -40.96 | -72.23 | -46.88 | 78.07 | 77.99 | -236.74 | -212.92 | 1.61 | -16.08 | 1.64 | -- | 24.39 | 98.78 | -55.66 | -- | -2.15 | -- |
BIO-TECHNE Corp | 1.15bn | 202.97m | 12.70bn | 3.05k | 64.09 | 6.30 | 40.50 | 11.00 | 1.26 | 1.26 | 7.16 | 12.79 | 0.4339 | 2.20 | 5.20 | 378,452.80 | 7.63 | 9.57 | 8.07 | 10.20 | 66.80 | 67.35 | 17.59 | 21.91 | 2.88 | 14.00 | 0.1619 | 24.19 | 2.81 | 12.07 | 4.88 | 25.13 | 12.81 | 0.00 |
Sarepta Therapeutics Inc | 1.40bn | 16.90m | 13.63bn | 1.31k | 1,810.47 | 14.18 | 232.14 | 9.72 | 0.0797 | 0.0797 | 14.75 | 10.17 | 0.4466 | 0.5758 | 4.66 | 1,067,960.00 | 0.5378 | -21.63 | 0.6577 | -25.75 | 88.18 | 86.65 | 1.20 | -77.05 | 3.44 | -- | 0.5632 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
Neurocrine Biosciences, Inc. | 1.98bn | 369.70m | 14.77bn | 1.45k | 40.34 | 6.19 | 37.67 | 7.45 | 3.64 | 3.64 | 19.47 | 23.72 | 0.6797 | 1.10 | 4.71 | 1,415,714.00 | 12.68 | 9.77 | 15.58 | 12.19 | 98.05 | 98.51 | 18.65 | 14.79 | 2.47 | -- | 0.049 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
United Therapeutics Corporation | 2.50bn | 1.05bn | 15.00bn | 1.17k | 16.01 | 2.80 | 13.57 | 6.00 | 21.13 | 21.13 | 50.24 | 120.76 | 0.3891 | 2.50 | 11.31 | 2,138,956.00 | 16.36 | 10.38 | 18.03 | 11.27 | 88.87 | 91.47 | 42.05 | 29.25 | 3.64 | -- | 0.101 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
BioNTech SE - ADR | 2.96bn | 122.68m | 20.43bn | 6.13k | 166.42 | 0.9424 | 62.04 | 6.89 | 0.5164 | 0.5164 | 12.33 | 91.20 | 0.1231 | 1.46 | 0.6733 | 483,212.50 | 0.5098 | 37.91 | 0.5488 | 44.76 | 79.38 | 83.82 | 4.14 | 50.36 | 11.16 | -- | 0.0117 | 4.73 | -77.94 | 97.35 | -90.14 | -- | 60.06 | -- |
ICON PLC | 8.23bn | 683.12m | 26.79bn | 41.10k | 39.25 | 2.84 | 21.04 | 3.25 | 8.24 | 8.24 | 99.33 | 114.08 | 0.4795 | -- | 2.92 | 200,291.60 | 3.98 | 3.93 | 4.80 | 4.80 | 29.67 | 28.91 | 8.30 | 7.37 | -- | 3.48 | 0.2706 | -- | 4.89 | 25.62 | 21.18 | 13.67 | 23.79 | -- |
Alnylam Pharmaceuticals, Inc. | 2.00bn | -332.08m | 29.71bn | 2.10k | -- | -- | -- | 14.83 | -2.71 | -2.71 | 15.78 | -1.73 | 0.5552 | 2.85 | 11.67 | 953,969.10 | -9.20 | -26.56 | -11.86 | -32.77 | 83.95 | 83.66 | -16.58 | -94.26 | 3.07 | -1.37 | 1.27 | -- | 76.23 | 89.45 | 61.08 | -- | -13.29 | -- |
Holder | Shares | % Held |
---|---|---|
Baillie Gifford & Co.as of 30 Jun 2024 | 8.28m | 3.48% |
PRIMECAP Management Co.as of 31 Mar 2024 | 4.81m | 2.02% |
Harding Loevner LPas of 31 Mar 2024 | 3.82m | 1.61% |
Flossbach von Storch AGas of 31 Mar 2024 | 3.47m | 1.46% |
Temasek Holdings Pte Ltd. (Investment Management)as of 31 Mar 2024 | 3.43m | 1.44% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 1.61m | 0.68% |
Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 943.12k | 0.40% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 828.93k | 0.35% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 814.00k | 0.34% |
Quinn Opportunity Partners LLCas of 31 Mar 2024 | 713.38k | 0.30% |